The Breast Cancer Research Foundation shared a post on LinkedIn:
“Diagnosed with triple-negative breast cancer just four months after giving birth to her second child, Marcella is grateful that research gave her the best possible outcome.
Thanks to the approval of Keytruda – based on the KEYNOTE-522 trial, led by several BCRF investigators – she was able to receive this groundbreaking treatment, which became available just a year before she needed it.
Research Is The Reason Marcella is a proud advocate and BCRF supporter, using her platform to fuel more research for current and future breast cancer patients.
Read Marcella’s story here.”
Proceed to the video attached to the post.
More posts featuring The Breast Cancer Research Foundation.